Free Trial
NASDAQ:BCLI

Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis

Brainstorm Cell Therapeutics logo
$0.70 -0.01 (-0.87%)
As of 09/12/2025 03:59 PM Eastern

About Brainstorm Cell Therapeutics Stock (NASDAQ:BCLI)

Key Stats

Today's Range
$0.66
$0.71
50-Day Range
$0.58
$1.31
52-Week Range
$0.52
$4.55
Volume
26,942 shs
Average Volume
564,261 shs
Market Capitalization
$7.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Brainstorm Cell Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
27th Percentile Overall Score

BCLI MarketRank™: 

Brainstorm Cell Therapeutics scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Brainstorm Cell Therapeutics are expected to grow in the coming year, from ($3.01) to ($1.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Brainstorm Cell Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Brainstorm Cell Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Brainstorm Cell Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.92% of the float of Brainstorm Cell Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Brainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in Brainstorm Cell Therapeutics has recently decreased by 1.61%, indicating that investor sentiment is improving.
  • Dividend Yield

    Brainstorm Cell Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Brainstorm Cell Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.92% of the float of Brainstorm Cell Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Brainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in Brainstorm Cell Therapeutics has recently decreased by 1.61%, indicating that investor sentiment is improving.
  • News Sentiment

    Brainstorm Cell Therapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Brainstorm Cell Therapeutics this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Brainstorm Cell Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.15% of the stock of Brainstorm Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 14.33% of the stock of Brainstorm Cell Therapeutics is held by institutions.

  • Read more about Brainstorm Cell Therapeutics' insider trading history.
Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BCLI Stock News Headlines

Alert: Prepare for Trump's Dollar Overhaul
President Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best."tc pixel
See More Headlines

BCLI Stock Analysis - Frequently Asked Questions

Brainstorm Cell Therapeutics' stock was trading at $2.27 at the start of the year. Since then, BCLI stock has decreased by 69.0% and is now trading at $0.7043.

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) posted its quarterly earnings results on Thursday, May, 15th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.07.
Read the conference call transcript
.

Brainstorm Cell Therapeutics shares reverse split before market open on Tuesday, October 1st 2024.The 1-15 reverse split was announced on Thursday, September 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Top institutional shareholders of Brainstorm Cell Therapeutics include Gunderson Capital Management Inc. (0.26%). Insiders that own company stock include Chaim Lebovits, Stacy Lindborg and Ibrahim B Dagher.
View institutional ownership trends
.

Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Brainstorm Cell Therapeutics investors own include CocaCola (KO), Organovo (ONVO), Cardium Therapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Protalix BioTherapeutics (PLX) and Isoray (ISR).

Company Calendar

Last Earnings
5/15/2025
Today
9/15/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCLI
CIK
1137883
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.62 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-519.50%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.21
Quick Ratio
0.21

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.36) per share
Price / Book
-0.52

Miscellaneous

Outstanding Shares
11,035,000
Free Float
8,742,000
Market Cap
$7.77 million
Optionable
Optionable
Beta
0.15

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:BCLI) was last updated on 9/15/2025 by MarketBeat.com Staff
From Our Partners